Astrocyte Function in Alcohol Reward and Addiction

Total Page:16

File Type:pdf, Size:1020Kb

Astrocyte Function in Alcohol Reward and Addiction lism and D ho ru o g lc D A e p f e o Journal of n l Adermark, J Alcohol Drug Depend 2015, 3:4 d a e n r n c u e o DOI; 10.4172/2329-6488.1000e123 J ISSN: 2329-6488 Alcoholism & Drug Dependence EditorialResearch Article OpenOpen Access Access Astrocyte Function in Alcohol Reward and Addiction Louise Adermark* Addiction Biology Unit, Sahlgrenska Academy, Institute of Neuroscience and Physiology, University of Gothenburg, Box 410, SE-405 30 Gothenburg, Sweden Abstract Glial cells, particularly astrocytes, play essential roles in the regulation of neurotransmission, metabolism, and supply of energy substrates for synaptic transmission. One astrocyte can receive inputs from several hundreds of synapses, and synchronized neuronal activity correlates with astrocyte calcium signaling. Astrocyte pathology is a common feature of ethanol exposure in both humans and animal models, and brief alcohol intake is sufficient to cause long-lasting changes in astrocyte gene expression, activity and proliferation. Recent research also suggests that astrocytes shape the rewarding sensation of ethanol, and might be involved in modulating alcohol consumption. Considering the role of astrocytes in regulating glutamate homeostasis, a crucial component of alcohol abuse disorders, the astrocyte might be an important target for the development of new pharmacological treatments of alcoholism. Keywords: Alcohol; Astrocytes; Astroglia; Glia; GFAP; Dopamine; dependent glutamate-glutamine cycle is required to maintain active Ethanol neurotransmission at excitatory terminals, but may also play a vital role for GABAergic neurotransmission [20,21]. Inhibitory transmission is Astrocytes further regulated by astrocytes through glycine transporters GlyT1 The astroglial cell, or astrocyte, is the most numerous cell type of and GlyT2, and GABA transporters GAT-1 and GAT-3 [22,23], the glial cell family. Astrocytes give structural and metabolic support while adenosine is transported through the equilibrative nucleoside to surrounding neurons and are pivotal for neuronal functioning and transporter 1 and 3 (ENT1, ENT3) [24,25]. signal processing in the CNS [1,2] (Figure 1). The end feet of astrocytic Astrocytic calcium signaling processes encapsulate blood vessels and participate in building up the blood brain barrier [3,4]. The contact with blood vessels also enables the Even though astrocytes are not electrically excitable they express astrocytes to provide neurons with lactate under anaerobic conditions receptors for the majority of neurotransmitters and neuromodulators [1,5] (Figure 1). The astrocyte was first acknowledged as the primary [26-31]. Upon activation, astrocytes generate various complex changes cell type responsible for potassium buffering 6[ ], and combined in intracellular Ca2+, which can initiate the release of gliotransmittors with the clearance of amino acids from the extracellular space, such as adenosine, D-serine and glutamate [32-35]. The main Ca2+- astrocytes warrants a high signal to noise ratio, and reduced receptor signaling pathway is mediated via G-protein receptor activated desensitization [7,8]. One single astrocyte can enwrap several neuronal phospholipase C (PLC) and formation of inositol (1,4,5) trisphosphate somata and receive inputs from thousands of synapses, enabling them (IP3) through hydrolysis of phosphatidylinositol 4,5-bisphosphate to sense and integrate synaptic activity [9,10]. Activation of astrocytes 2+ (PIP2), which induces Ca -release from internal stores. Photorelease of also appears to be a crucial component for the induction of synaptic 2+ Ca or IP3 within a single astrocyte is also sufficient to cause glutamate- plasticity mechanisms, and both long-term potentiation (LTP) and release and to modulate neuronal excitation [32,34,36-40]. In addition long-term depression (LTD) in the hippocampus may be regulated by to Ca2+ release from internal stores, activation of G-coupled receptors astrocytes [11,12]. can also initiate influx of Ca2+ through different types of voltage- Astrocytes enwrap both presynaptic and postsynaptic terminals, independent Ca2+ channels [41,42] (Figure 2). forming the tripartite synapse. Astrocytic end feet encapsulate blood Intracellular Ca2+-signaling is primarily mediated through IP - vessels, enabling the astrocyte to give metabolic support to surrounding 3 gated release of Ca2+ from internal stores, which may be followed by neurons. Astrocytic clearance of neuroactive substances is crucial for Ca2+-influx through Ca2+ channels. Gap junction channels, which synaptic transmission. The excitatory amino acid glutamate (Glu) is are dynamically regulated by neuronal activity and intracellular rapidly metabolized to its non-excitable precursor glutamine (Gln), 2+ released back to the extracellular space, and taken up by neurons for homeostasis, allow Ca waves to spread through the astrocytic network. synthesis of glutamate or GABA. See text for further details. (CIF = Calcium Influx Factor; DOCC = Depletion-Operated Calcium Astrocytic transporters One of the most prominent functions of the astrocyte is the *Corresponding author: Louise Adermark, Addiction Biology Unit, Sahlgrenska clearance of glutamate, and astrocytic glutamate transporters EAAT2 Academy, Institute of Neuroscience and Physiology, University of Gothenburg, (GLT-1) and EAAT1 (GLAST) are the most abundant transporters Box 410, SE-405 30 Gothenburg, Sweden, Tel: +46-31 786-3975; E-mail: [email protected] for removal of glutamate in the brain [13]. Impaired astrocytic glutamate clearance appears to contribute to neuronal dysfunction Received: July 13, 2015; Accepted: July 16, 2015; Published: July 20, 2015 and degeneration in Huntington’s disease, major depressive disorder Citation: Adermark L (2015) Astrocyte Function in Alcohol Reward and Addiction. and Alzheimer’s disease [14-17], and might also play a role in alcohol J Alcohol Drug Depend 3: e123. doi:10.4172/23296488.1000e123 abuse [18]. Following reuptake, glutamate is converted by glutamine Copyright © 2015 Adermark L. This is an open-access article distributed under synthetase to its non-excitable precursor glutamine, which is released the terms of the Creative Commons Attribution License, which permits unrestricted back to the extracellular space [19] (Figure 1). This astrocyte- use, distribution, and reproduction in any medium, provided the original author and source are credited. J Alcohol Drug Depend ISSN: 2329-6488 JALDD, an open access journal Volume 3 • Issue 4 • 1000e123 Citation: Adermark L (2015) Astrocyte Function in Alcohol Reward and Addiction. J Alcohol Drug Depend 3: e123. doi:10.4172/23296488.1000e123 Page 2 of 6 Channel; SMOCC = Second Messenger-Operated Calcium Channel; with development, differentiation and functional activity [58]. Many ROCC = Receptor-Operated Calcium Channel; ER = Endoplasmic membrane proteins, such as ion channels, transporters, receptors, Reticulum). enzymes and G-proteins are affected by ethanol in ways that lead to long-lasting changes in activity and gene expression [59], and astrocytes Gap junction channels appear to be important target cells. Brief ethanol-exposure is sufficient Astrocytes are highly interconnected through gap junction to alter astrocytic gene expression and to restrict proliferation [60,61], channels, built up by the protein connexin [43]. These gap junction and may acutely impair astrocytic regulation of neurotransmission. channels concede bidirectional diffusion of charged and uncharged Ethanol elevates intracellular calcium in a subset of astrocytes and small molecules allowing Ca2+ waves to spread through the astrocytic reduces gap junction coupling in a brain region selective manner, syncytium [44]. Functional gap junctions might also exist between which could selectively affect signal processing 62-64[ ]. Considering + astrocytes and oligodendrocytes and to some extent neurons [45-47]. that gap junction coupling equalizes [Na ]i, the decline in connectivity Coupling at gap junctions is regulated by intracellular ion homeostasis might also reduce the capacity for amino acid uptake and potassium and influenced by neuronal activity and released neuroactive substances buffering, as well as lead to failure in coordinating other physiological such as growth hormones, glutamate, 5-HT, ATP, and potassium [48- responses that involves sodium [65,66]. Diminished immunoreactive 53] (Figure 2). Connexins also form plasma membrane channels, puncta, and reduced levels of the gap junction protein connexin 43, hemi channels, through which gliotransmitters can be released is also seen in post mortem studies of subjects with alcohol abuse [54,55]. Connexin-43 hemi channels are necessary for fear memory disorder, supporting a role for altered connectivity or hemi channel- consolidation and has been suggested as pharmacological targets for based communication in the pathophysiology of alcoholism [67]. treatment of post-traumatic stress disorder, but dysregulations of hemi Astrocytic cell swelling channel properties could also be critical during homeostatic imbalances [54,56]. Importantly, the connectivity of the astrocyte network, as well Ethanol induces cell swelling in a subset of astrocytes, which could as individual cells, appears to be brain region selective, where astrocytes lead to changes in size and geometry of the extracellular space and in the striatum are highly interconnected and primarily categorized as thereby altered volume transmission [64,68-70]. Swelling of the end passive, while a larger proportion
Recommended publications
  • Inositol Safety: Clinical Evidences
    European Review for Medical and Pharmacological Sciences 2011; 15: 931-936 Inositol safety: clinical evidences G. CARLOMAGNO, V. UNFER AGUNCO Obstetrics & Gynecology Center, Rome (Italy) Abstract. – Myo-inositol is a six carbon ent required by the human cells for the growth cyclitol that contains five equatorial and one axi- and survival in the culture. In humans and other al hydroxyl groups. Myo-inositol has been classi- species, Myo-inositol can be converted to either fied as an insulin sensitizing agent and it is L- or D-chiro-inositol by epimerases. Early stud- commonly used in the treatment of the Polycys- tic Ovary Syndrome (PCOS). However, despite ies showed that inositol urinary clearance was al- its wide clinical use, there is still scarce informa- tered in type 2 diabetes patients, the next step tion on the myo-inositol safety and/or side ef- was to link impaired inositol clearance with in- fects. The aim of the present review was to sum- sulin resistance (for a review see1). Because of marize and discuss available data on the myo-in- these properties, inositol have been classified as ositol safety both in non-clinical and clinical set- “insulin sensitizing agent”2. tings. The main outcome was that only the highest In the recent years, inositol has found more dose of myo-inositol (12 g/day) induced mild and more space in the reproductive clinical prac- gastrointestinal side effects such as nausea, fla- tice3-6. Indeed, since the main therapy for Poly- tus and diarrhea. The severity of side effects did cystic Ovary Syndrome (PCOS) is the use of in- not increase with the dosage.
    [Show full text]
  • Revisions to USP 31–NF 26, Second Supplement
    Revisions to USP 31–NF 26, Second Supplement (published May 2008) Published April 2008 General Chapters Monographs:A–C D–N O–S T–Z Monograph Title Section Head Scientific Liaison DANTROLENE SODIUM Dissolution <711> CAPSULES PF 33(4) Pg. 645 DEHYDROACETIC ACID PF 33(4) Title Pg. 703 DEHYDROACETIC ACID PF 33(4) Chemical Info Pg. 703 DEHYDROACETIC ACID PF 33(4) Definition Pg. 703 DEHYDROACETIC ACID PF 33(4) Packaging and storage Pg. 703 DEHYDROACETIC ACID PF 33(4) USP Reference standards <11> Pg. 703 DEHYDROACETIC ACID PF 33(4) Identification Pg. 703 DEHYDROACETIC ACID PF 33(4) Heavy Metals, Method II <231> Pg. 703 DEHYDROACETIC ACID PF 33(4) Loss on drying <731> Pg. 703 DEHYDROACETIC ACID PF 33(4) Melting range, Class I <741> Pg. 703 DEHYDROACETIC ACID PF 33(4) Residue on ignition <281> Pg. 703 DEHYDROACETIC ACID PF 33(4) Assay Pg. 703 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Title 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Definition 784 file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM] DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Packaging and storage 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Labeling 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. USP Reference stadards 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Identification 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Uniformity of dosage units 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Loss on drying 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg.
    [Show full text]
  • Genetic Control of Apigenin Di-C-Glycoside Biosynthesis in Bread Wheat Grain and Their Role
    Genetic control of Apigenin di-C-glycoside biosynthesis in bread wheat grain and their role as yellow pigments of Asian alkaline noodles Submitted by Grace Yasmein Wijaya This thesis is submitted to Faculty of Sciences in fulfilment of the requirements for the degree Doctor of Philosophy Faculty of Science The University of Adelaide November 2012 This book is An Answer to Prayers of a Long list of Believers I have been very blessed and loved with all of your spiritual supports, for His guidance and protections, and sincerely will not have enough to thank you all..... May you all be blessed and loved, too As I have been always, yasmein Table of Content Table of Content i List of Tables x List of Figures xiii List of Supplemental Materials xxv Summary xxx Statement of Authorship xxxiv List of Publications xxxv Acknowledgement xxxvi List of Abbreviations xxxix Chapter I: General Introduction 1 1.1 Background 1 1.2 Knowledge Gap 2 1.3 Structure of thesis 2 Chapter II: Literature review 4 2.1 Asian noodles as one of the major end-products of Australian bread wheat 4 2.2 Yellow colour of YAN 5 2.2.1 Natural Compounds that contribute to the yellow colour of YAN 5 2.2.1.1 Types of natural compounds that contributes to the yellow colour of YAN and their roles in plants and human health 5 2.2.1.2 Contribution of xanthophylls and ACGs to the yellow colour of alkaline noodles 8 2.2.2 Factors influencing the measurement of the yellowness of noodles and the content of xanthophyll and ACG in wheat grain 10 i 2.2.3 The amount, tissue location and composition
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Inositol (Powder) Introduced 2008
    Product Information Sheet – March 2016 Inositol (powder) Introduced 2008 What Is It? Inositol (powder) Inositol is a component of the B-complex family. It supports healthy two scoops (approximately 4.2 g) contain v central nervous system function, including emotional wellness, healthy mood and behavior. Additionally, it may promote ovarian health.* inositol (as myo-inositol) .................................................................................4.2 g serving size: approximately 4.2 g (2 scoops) Uses For Inositol (powder) servings per container: 60 Emotional Wellness: Myo-inositol is the primary form of inositol 2 scoops, 1–2 times daily, with or between meals, or as directed found in the central nervous system. It plays an important role in cell by a health professional. membrane formation and serves as part of the phosphatidylinositol second messenger system, supporting serotonin, norepinenephrine and cholinergic receptor function. As a result, inositol may support healthy mood, emotional wellness and behavior, and ease occasional nervous tension.* Ovarian Function: Research suggests that myo-inositol may help to support healthy ovulatory activity, ovarian function and reproductive system function.* What Is The Source? Myo-inositol is derived from rice bran. Recommendations Pure Encapsulations® recommends 2 scoops, 1–2 times daily, with or between meals, or as directed by a health professional. Are There Any Potential Side Effects Or Precautions? Rarely, inositol has been associated with nausea, fatigue, headache or dizziness. If pregnant or lactating, consult your physician before taking this product. Are There Any Potential Drug Interactions? At this time, there are no known adverse reactions when taken in conjunction with medications. Consult your physician for more information. *These statements have not been evaluated by the Food and Drug Administration.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Synthesis of Mannosylglucosaminylinositol
    Proc. Nati. Acad. Sci. USA Vol. 89, pp. 6025-6029, July 1992 Medical Sciences Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells (complement/decay-accelerating factor/CD59) SHINICHI HIROSE*, LAKSHMESWARI RAVI*, GREGORY M. PRINCE*, MELVIN G. ROSENFELDt, ROBERT SILBERf, STEVEN W. ANDRESEN§, SANDRA V. HAZRA¶, AND M. EDWARD MEDOF*II *Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106; Departments of tCell Biology and *Medicine, New York University Medical Center, New York, NY 10016; §Cleveland Clinic Foundation, Cleveland, OH 44106; and lAkron General Medical Center, Akron, OH 44307 Communicated by Frederick C. Robbins, November 29, 1991 (received for review September 12, 1991) ABSTRACT To identify mannosyl (Man)-containing inter- have been identified, information concerning the biochemical mediates ofthe human glycoinositol phospholipid (GPI) anchor pathway(s) responsible for their intracellular GPI-anchor pathway and examine their expression in paroxysmal nocturnal assembly and protein incorporation is only beginning to hemoglobinuria (PNH), mannolipid products deriving from in emerge. vitro guanosine diphosphate [3HJMan labeling of HeLa cell Among human GPI-anchored proteins are the decay- microsomes were characterized. The defined GPI species were accelerating factor (DAF) and CD59, membrane-associated correlated with products deriving from in vivo [3HJMan label- regulators of the complement cascade which protect host ing of normal and (GPI-anchor defective) affected leukocytes. tissues from autologous complement attack (reviewed in refs. In vitro analyses in HeLa cells showed dolichol-phosphoryl 2-4). Deficient expression of these proteins underlies an (Dol-P)-[3H]Man and a spectrum of [3H]Man lipids exhibiting acquired hemolytic disorder termed paroxysmal nocturnal TLC mobilities approximating those of Trypanosoma brucei hemoglobinuria (PNH), and the lesion responsible for the (Tryp) GPI precursors.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Inhibition of Vessel Permeability by TNP-470 and Its Polymer Conjugate, Caplostatin
    ARTICLE Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin Ronit Satchi-Fainaro,1 Roni Mamluk,1 Ling Wang,3 Sarah M. Short,1 Janice A. Nagy,2 Dian Feng,2 Ann M. Dvorak,2 Harold F. Dvorak,2 Mark Puder,1 Debabrata Mukhopadhyay,2,3 and Judah Folkman1,* 1Children’s Hospital Boston and Harvard Medical School, Vascular Biology Program, Department of Surgery, 1 Blackfan Circle, Karp Family Research Laboratories, Floor 12, Boston, Massachusetts 02115 2 Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215 3 Biochemistry and Molecular Biology and Mayo Cancer Center, Mayo Clinic, Rochester, Minnesota 55905 *Correspondence: [email protected] Summary Angiogenesis inhibitors, such as TNP-470 and the nontoxic HPMA copolymer-TNP-470 (caplostatin), are emerging as a class of anticancer drugs. We report that TNP-470 and caplostatin inhibit vascular hyperpermeability of tumor blood vessels as well as that induced in mouse skin by different mediators. Treatment with TNP-470 or angiostatin for 3 days was sufficient to reduce permeability of tumor blood vessels, delayed-type hypersensitivity, and pulmonary edema induced by IL-2. TNP-470 also inhibited VPF/VEGF-induced phosphorylation of VEGFR-2, calcium influx, and RhoA activation in endothelial cells. These results identify an activity of TNP-470, that of inhibiting vessel hyperpermeability. This activity likely contributes to TNP-470’s antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer and inflammation. Introduction vival, and permeability) by activating VEGFR-2 (Claesson- Welsh, 2003). Angiogenesis, the generation of new blood vessels from preex- While EC proliferation is an important component of angio- isting microvasculature (Folkman and Kalluri, 2003), is regu- genesis (Koch et al., 1994), VPF/VEGF has relatively weak mi- lated by a number of different growth factors (Matsumoto and togenic activity compared to other factors such as basic fibro- Claesson-Welsh, 2001).
    [Show full text]
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
    [Show full text]
  • Targeting HDAC Complexes in Asthma and COPD
    epigenomes Review Targeting HDAC Complexes in Asthma and COPD Martijn R. H. Zwinderman, Sander de Weerd and Frank J. Dekker * Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9713 AV Groningen, The Netherlands * Correspondence: [email protected]; Tel.: +31-50-363-8030 Received: 28 June 2019; Accepted: 4 September 2019; Published: 7 September 2019 Abstract: Around three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD. The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway inflammation show promising results, but several challenges still need to be overcome. One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments. Keywords: asthma; COPD; inflammation; NF-κB; HDAC; acetylation; post translational modification (PTM); inhibitor; drug design; co-repressor complex; review 1. Introduction Inflammatory pulmonary diseases are among the most common health problems worldwide. Currently, approximately 339 million people suffer from asthma, which results in 250 thousand preventable deaths annually [1,2]. Similar numbers have been reported for Chronic Obstructive Pulmonary Disease (COPD). About 384 million people were estimated to have COPD and 3 million people died because of it in 2010 [3–6].
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]